Key facts
- This page summarizes Michael Craig Pine's Form 4 filing for EyePoint Pharmaceuticals, Inc. (EYPT).
- 5 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 09 Jan 2024, 21:11.
Michael Craig Pine - 05 Jan 2024 Form 4 Insider Report for EyePoint Pharmaceuticals, Inc. (EYPT)
- Reporting relationship
- Chief Corp Dev.&Strat. Officer
- Issuer ticker
- EYPT
- Reported as of
- 05 Jan 2024
- Net transaction value
- -$121,706
- SEC form
- 4
- Accepted by SEC
- 09 Jan 2024, 21:11:46 UTC
- Prior SEC filing
- 11 Dec 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Ron Honig, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Michael Craig Pine filed Form 4 for EyePoint Pharmaceuticals, Inc. (EYPT) on 09 Jan 2024.
Change
- Previous filing in this sequence was filed on 11 Dec 2023.
- Current net transaction value: -$121,706.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
EYPT
transaction
Common Stock
Options Exercise
- Transaction value
- $0
- Shares
- +15,285
- Change %
- +352%
- Price
- $0.000000
- Shares after
- 19,628
- Date
- 06 Jan 2024
- Ownership
- Direct
EYPT
transaction
Common Stock
Tax liability
- Transaction value
- $121,706
- Shares
- -5,966
- Change %
- -30%
- Price
- $20.40
- Shares after
- 13,662
- Date
- 06 Jan 2024
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
EYPT
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +21,000
- Change %
- Price
- $0.000000
- Shares after
- 21,000
- Date
- 05 Jan 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 21,000
- Exercise price
- $0.000000
- Footnotes
- F2
EYPT
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +42,000
- Change %
- Price
- $0.000000
- Shares after
- 42,000
- Date
- 05 Jan 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 42,000
- Exercise price
- $20.40
- Footnotes
- F3
EYPT
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -15,285
- Change %
- -33%
- Price
- $0.000000
- Shares after
- 30,570
- Date
- 06 Jan 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 15,285
- Exercise price
- $0.000000
- Footnotes
- F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units
Footnote F2
The restricted stock units will vest in three ratable annual installments beginning January 5, 2025.
Footnote F3
The option to purchase will vest and become exercisable as follows: 25% at January 5th, 2025 and the remainder ratably, on a monthly basis, over the remaining three years.
Footnote F4
The restricted stock units vests in three ratable annual installments beginning January 6, 2024.